Abstract:AIMS:Currently, there are many approaches available for neoadjuvant therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer that improve therapeutic efficacy but are also controversial. We conducted a two-step Bayesian network meta-analysis (NMA) to compare odds ratios (ORs) for pathologic complete response (PCR) and safety endpoints.METHODS:The Cochrane Central Register of Controlled Trials, PubMed, Embase, and online abstracts from the American Society of Clinical Oncology and San Antonio Breast Cancer Symposium were searched comprehensively and systematically. Phase II/III randomised clinical trials for targeted therapy in at least one arm were included.RESULTS:A total of 9779 published manuscripts were identified, and 36 studies including 10,379 patients were finally included in our analysis. The NMA of PCR showed that dual-target therapy is better than single-target therapy and combination chemotherapy is better than monochemotherapy. However, anthracycline did not bring extra benefits, whether combined with dual-target therapy or single-target therapy. On the other hand, the addition of endocrine therapy in the HER2-positive, hormone receptor (HR)-positive subgroup might have additional beneficial effects but without significant statistical difference. By performing a conjoint analysis of the PCR rate and safety endpoints, we found that 'trastuzumab plus pertuzumab' and 'T-DM1 containing regimens' were well balanced in terms of efficacy and toxicity in all target regimens.CONCLUSION:In summary, trastuzumab plus pertuzumab-based dual-target therapy with combination chemotherapy regimens showed the highest efficacy of all optional regimens. They also achieved the best balance between efficacy and toxicity. As our study showed that anthracycline could be replaced by carboplatin, we strongly recommended TCbHP as the preferred choice for neoadjuvant treatment of HER2-positive breast cancer. We also look forward to the potential value of T-DM1 in improving outcomes, which needs further study in future trials.

Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Overuse of Neo-adjuvant Chemotherapy for Primary Breast Cancer

Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer

Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer

Efficacy and Safety of Neoadjuvant Therapy for HER2-positive Early Breast Cancer: a Network Meta-Analysis

Post-Neoadjuvant Treatment Strategies in Breast Cancer

The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment

Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies

Neoadjuvant or adjuvant chemotherapy in early breast cancer?

Recent advances in neoadjuvant therapy for breast cancer

Current and future role of neoadjuvant therapy for breast cancer

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer

Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives

Endocrine Therapy As Adjuvant or Neoadjuvant Therapy for Breast Cancer: Selecting the Best Agents, the Timing and Duration of Treatment

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies

Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer

Landscape of Neoadjuvant Therapy for Breast Cancer